Belite Bio
BLTE
8 hedge funds and large institutions have $25.4M invested in Belite Bio in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 0 closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
0.03% less ownership
Funds ownership: 3.56% → 3.53% (-0.03%)
2% less capital invested
Capital invested by funds: $25.9M → $25.4M (-$472K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$21.2K |
| 2 |
AWS
Atria Wealth Solutions
New York
|
+$10.1K |
| 3 |
BlackRock
New York
|
+$5.65K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$125K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$94K |
| 3 |
Morgan Stanley
New York
|
-$29.2K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$9.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWS
1
Atria Wealth Solutions
New York
| $24.3M | +$10.1K | +333 | +0% |
|
|
AA
2
ALPS Advisors
Denver,
Colorado
| $458K | -$9.15K | -301 | -2% |
|
|
3
State Street
Boston,
Massachusetts
| $362K | +$21.2K | +696 | +6% |
|
|
4
Qube Research & Technologies (QRT)
London,
United Kingdom
| $219K | -$94K | -3,093 | -29% |
|
|
5
BlackRock
New York
| $31.6K | +$5.65K | +186 | +21% |
|
|
6
Morgan Stanley
New York
| $31K | -$29.2K | -962 | -48% |
|
|
7
UBS Group
Zurich,
Switzerland
| $3.59K | -$125K | -4,097 | -97% |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$2.86K | +94 | New |
|
BLTE Hedge Fund Activity: Q1 2023 in Review
8 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q1 2023, worth a combined $25.4M — down 1.8% from $25.9M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BLTE positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was State Street, adding an estimated $21.2K. The largest seller was UBS Group, cutting an estimated $125K.
- 8 institutional investors held Belite Bio (BLTE) as of Q1 2023, up from 7 in Q4 2022.
- Funds reported $25.4M of Belite Bio stock for Q1 2023, down 1.8% quarter-over-quarter.
- 1 fund opened new Belite Bio positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest Belite Bio buyer in Q1 2023 was State Street, an estimated $21.2K added.
- The largest Belite Bio seller in Q1 2023 was UBS Group, an estimated $125K sold.
Based on aggregated 13F filings for Q1 2023.